GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » ROC %

Andros Pharmaceuticals Co (ROCO:6917) ROC % : -95.69% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Andros Pharmaceuticals Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -95.69%.

As of today (2024-12-12), Andros Pharmaceuticals Co's WACC % is 9.91%. Andros Pharmaceuticals Co's ROC % is -105.48% (calculated using TTM income statement data). Andros Pharmaceuticals Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Andros Pharmaceuticals Co ROC % Historical Data

The historical data trend for Andros Pharmaceuticals Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co ROC % Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
-105.30 -70.61 -64.23 -82.03 -99.04

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC % Get a 7-Day Free Trial Premium Member Only -96.54 -86.57 -71.54 -114.11 -95.69

Andros Pharmaceuticals Co ROC % Calculation

Andros Pharmaceuticals Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-73.71 * ( 1 - -0.03% )/( (66.934 + 81.955)/ 2 )
=-73.732113/74.4445
=-99.04 %

where

Andros Pharmaceuticals Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-76.294 * ( 1 - 0.1% )/( (81.955 + 77.339)/ 2 )
=-76.217706/79.647
=-95.69 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=480.247 - 13.017 - ( 397.922 - max(0, 18.623 - 408.514+397.922))
=77.339

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Andros Pharmaceuticals Co  (ROCO:6917) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Andros Pharmaceuticals Co's WACC % is 9.91%. Andros Pharmaceuticals Co's ROC % is -105.48% (calculated using TTM income statement data). Andros Pharmaceuticals Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Andros Pharmaceuticals Co ROC % Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Andros Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co Headlines

No Headlines